alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › secondary

secondary

3 studies tagged secondary, dated 2013-06-05 to 2024-01-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer's Disease: Secondary Analyses from the A4 Study 2024-01-01
  2. Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease 2023-03-31
  3. Screening of biochemical and molecular mechanisms of secondary injury and repair in the brain after experimental blast-induced traumatic brain injury in rats 2013-06-05

Studies

3 studies carry this tag.

Date range

2013 to 2024

Top journals

  • Annals of clinical and translational neurology 1
  • Journal of neurotrauma 1
  • The journal of prevention of Alzheimer's disease 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer's Disease: Secondary Analyses from the A4 Study

    ✓ Peer-reviewed alzhub usefulness score 82 out of 100. The journal of prevention of Alzheimer's disease 2024-01-01 Cognitive tests and assessment

    This study provides corroborating evidence that solanezumab does not slow cognitive decline in preclinical AD as exhibited with a computerized cognitive assessment with some evidence that solanezumab may exacerbate cognition on select digital outcomes.

  2. Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Annals of clinical and translational neurology 2023-03-31 Biomarkers

    Linear models showed that plasma GFAP was significantly higher in αSyn+AD compared to αSyn (β = 0.31, 95% CI = 0.065-0.56, and P = 0.015), after covarying for age at plasma, plasma-to-death interval, and sex; plasma p-tau 181 was not (P = 0.37).

  3. Screening of biochemical and molecular mechanisms of secondary injury and repair in the brain after experimental blast-induced traumatic brain injury in rats

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of neurotrauma 2013-06-05 Biomarkers

    Ascorbate, LMWT, and protein thiols were reduced at 2 and 24 h; by 24 h, HNE was increased.

All topic tags with their study counts